Alternative Data for Alzamend Neuro
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,846 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Alzamend Neuro
None
| Price | $2.25 |
| Target Price | Sign up |
| Volume | 19,780 |
| Market Cap | $8.6M |
| Year Range | $1.82 - $5.92 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Ascendiant Capital Markets Has Lowered Expectations for Alzamend Neuro (NASDAQ:ALZN) Stock PriceSeptember 26 - ETF Daily News |
|
Alzamend Neuro (ALZN) to Release Earnings on WednesdaySeptember 7 - ETF Daily News |
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech: 1,775 Deals + SEC Contracts, Top 25 Dealmaker Profiles, 2020-2025October 13 - GlobeNewswire |
|
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsightSeptember 11 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 0 | 0 | 0 | -1M | -1,000,000 | -0.300 |
| Q3 '25 | 0 | 28,000 | -28,000 | -2.7M | -2.7M | -1.280 |
| Q2 '25 | 0 | 13,000 | -13,000 | -1.1M | -1.1M | -9.480 |
| Q1 '25 | 0 | 13,000 | -13,000 | -1M | -1M | -1.710 |
| Q4 '24 | 0 | 13,000 | -13,000 | -1.4M | -1.3M | -3.600 |
Insider Transactions View All
| McGrath Lynne Fahey filed to sell 25 shares at $2.3. October 24 '25 |
| AULT MILTON C III filed to sell 8,260 shares at $2.3. October 10 '25 |
| AULT MILTON C III filed to sell 28,657 shares at $2.4. October 10 '25 |
Similar companies
Read more about Alzamend Neuro (ALZN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Alzamend Neuro
The Market Cap of Alzamend Neuro is $8.6M.
Currently, the price of one share of Alzamend Neuro stock is $2.25.
The ALZN stock price chart above provides a comprehensive visual representation of Alzamend Neuro's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Alzamend Neuro shares. Our platform offers an up-to-date ALZN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Alzamend Neuro (ALZN) does not offer dividends to its shareholders. Investors interested in Alzamend Neuro should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Alzamend Neuro are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
